Hospira HSP

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Bull Market: More to Run

      Headlines

      Mon, 2 Mar 2015

      Pfizer ( PFE ) announced the acquisition of Hospira ( HSP ) for $90 per share or $17 billion ..... premium on top of a large run-up for Hospira , the biggest provider of injectable drugs ..... the market has significantly undervalued Hospira . After a long hiatus, M&A bounced

    2. Hospira Adjusts to Generic Precedex Challenge

      Commentary

      Thu, 12 Feb 2015

      We think Hospira posted a decent fourth quarter, considering ..... purchase the company. We continue to believe Hospira 's biosimilars pipeline, the recent ..... overcome the recent patent loss on Precedex. Hospira 's narrow economic moat remains intact

    3. Friday Five: What Will the Fed Do Now?

      Video Reports

      Fri, 6 Feb 2015

      stock news, [TICKER:PFE] Pfizer (PFE) announced that it's paying a pretty decent premium to acquire [TICKER:HSP] Hospira (HSP). What's our take on that deal? Glaser: Damien Conover, our Pfizer analyst, thinks that it's going to be a

      Hospira found at 3:28

      Pfizer (PFE) announced that it's paying a pretty decent premium to acquire [TICKER:HSP] Hospira (HSP). What's our take on that deal? Glaser: Damien Conover, our Pfizer analyst, thinks that it's going to be a good one
    4. UPDATE 3-Pfizer to buy Hospira for $15 bln to bolster hospital products

      Headlines

      Thu, 5 Feb 2015

      Feb 5 (Reuters) - Pfizer Inc said it would buy Hospira Inc for about $15 billion to boost its portfolio of generic injectable drugs and copies of biotech medicines.

    5. Pfizer's Acquisition of Hospira Strengthens Its Moat at a Fair Price

      Headlines

      Thu, 5 Feb 2015

      Pfizer's PFE announced acquisition of Hospira HSP doesn't materially change our fair ..... price. However, we plan to raise our Hospira fair value estimate to the acquisition ..... specialty injectable pharmaceuticals (68% of Hospira sales), which should strengthen the

    6. Pfizer's Acquisition of Hospira Strengthens Its Moat at a Fair Price

      Commentary

      Thu, 5 Feb 2015

      Pfizer's announced acquisition of Hospira doesn't materially change our fair value ..... price. However, we plan to raise our Hospira fair value estimate to the acquisition ..... specialty injectable pharmaceuticals (68% of Hospira sales), which should strengthen the

    7. Amgen's Biosimilar Headwinds Poised to Increase in 2015, but We're Bullish on Upcoming Launches

      Commentary

      Wed, 28 Jan 2015

      by the end of the year). However, Novartis' Zarxio is poised to launch this year as another competitor to Neupogen, and Hospira has filed for approval of a biosimilar Epogen. This puts pressure on Amgen's pipeline, and we think the potential August

    8. Nominees for 2014 Domestic-Stock Fund Manager of the Year

      Headlines

      Mon, 5 Jan 2015

      shows more downside risk. At American Century Mid Cap Value, which is closed to new investors, health-care stocks such as Hospira HSP and LifePoint Hospitals LPNT have helped this past year, and so has some serendipitous merger and acquisition activity

    9. From Barron’s, December 1, 2014 (Part 2)

      Commentary

      Sat, 29 Nov 2014

      Bearish stories: Ag stocks [ DE, AGCO; POT, SYT ; decline in commodity prices has yet to be played out; pg 20]; Hospira [ HSP ; pg 20]; Hawaiian Electric [ HE ; very high electricity costs – triple that in the US mainland – has regulators

    10. UPDATE 2- Hospira profit beats estimates on higher prices, sales

      Headlines

      Thu, 6 Nov 2014

      * Shares rise as much as 9 pct to a 3-year high (Adds analyst comments, background, updates shares)

    « Prev12345Next »
    Content Partners